Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
7.52
-0.25 (-3.22%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Q32 Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 53.74 | 53.74 | - | -6.65 | 6.65 | - | |
Revenue Growth | - | - | - | - | - | - |
Cost of Revenue | 14.35 | 19.16 | 48.14 | 31.73 | 35.81 | 29.93 |
Gross Profit | 39.39 | 34.58 | -48.14 | -38.38 | -29.16 | -29.93 |
Selling, General & Admin | 17.93 | 17.68 | 17.96 | 9.88 | 10.06 | 6.76 |
Operating Expenses | 17.93 | 17.68 | 17.96 | 9.88 | 10.06 | 6.76 |
Operating Income | 21.46 | 16.9 | -66.1 | -48.26 | -39.23 | -36.69 |
Interest Expense | -0.9 | -1.1 | -1.4 | -2 | - | - |
Interest & Investment Income | 1.78 | 2.2 | 3.9 | - | - | - |
Earnings From Equity Investments | - | - | -1.63 | - | - | - |
Other Non Operating Income (Expenses) | -0.08 | 0.16 | 2.3 | 3.02 | -3.52 | -0.32 |
EBT Excluding Unusual Items | 22.27 | 18.16 | -62.93 | -47.23 | -42.75 | -37.02 |
Gain (Loss) on Sale of Investments | -0.07 | -0.07 | -0.68 | - | - | - |
Gain (Loss) on Sale of Assets | 11.74 | 11.74 | - | - | - | - |
Other Unusual Items | -0.15 | - | 15.89 | -6.19 | - | - |
Pretax Income | 33.79 | 29.82 | -47.71 | -53.43 | -42.75 | -37.02 |
Income Tax Expense | - | - | 0.02 | 0.32 | 0.06 | 0.55 |
Net Income | 33.79 | 29.82 | -47.73 | -53.74 | -42.81 | -37.56 |
Net Income to Common | 33.79 | 29.82 | -47.73 | -53.74 | -42.81 | -37.56 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 15 | 12 | 9 | 0 | 7 | 6 |
Shares Outstanding (Diluted) | 15 | 12 | 10 | 0 | 7 | 6 |
Shares Change | 21.91% | 27.51% | 2666.77% | -95.03% | 8.57% | - |
EPS (Basic) | 2.28 | 2.42 | -5.12 | -153.96 | -6.09 | -5.81 |
EPS (Diluted) | 2.27 | 2.42 | -6.58 | -153.96 | -6.09 | -5.81 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -19.83 | -33.54 | -67.79 | -18.68 | -13.44 | -33.14 |
Free Cash Flow Per Share | -1.33 | -2.72 | -7.02 | -53.52 | -1.91 | -5.12 |
Gross Margin | 73.30% | 64.35% | - | - | - | - |
Operating Margin | 39.94% | 31.45% | - | - | -589.76% | - |
Profit Margin | 62.87% | 55.49% | - | - | -643.65% | - |
Free Cash Flow Margin | -36.90% | -62.42% | - | - | -202.10% | - |
EBITDA | 21.82 | 17.29 | -65.62 | -47.76 | -38.86 | -36.65 |
EBITDA Margin | 40.60% | 32.18% | - | - | - | - |
D&A For EBITDA | 0.36 | 0.39 | 0.49 | 0.5 | 0.37 | 0.05 |
EBIT | 21.46 | 16.9 | -66.1 | -48.26 | -39.23 | -36.69 |
EBIT Margin | 39.94% | 31.45% | - | - | - | - |